Karyopharm Therapeutics Inc.

KPTI

Healthcare|Biotechnology|US

$0.05

-0.01 (-8.65%)

Cash / Share

$2.25

Next Earnings Report

Feb 10, 2027

EPS est. -$0.74 · Revenue est. $34.1M

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest May 4, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (14)

Dec 2026

Est. completion

P2Diffuse Large B-cell Lymphoma

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251n=244

Dec 2026

Est. completion

P2P3Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022n=501

Dec 2026

Est. completion

P2Lymphoma

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707n=129

Feb 2027

Est. completion

P1Relapsed Myelodysplastic Syndrome

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

NCT06399640n=60

Apr 2027

Est. completion

P1P2Multiple Myeloma

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042n=300

Jun 2027

Est. completion

P2Myelofibrosis

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806n=58

Jul 2027

Est. completion

P1P2Relapse Multiple Myeloma

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07479979n=62

Jan 2028

Est. completion

P2Multiple Myeloma, Refractory

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

NCT04414475n=127

Feb 2028

Est. completion

P2Multiple Myeloma

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137n=96

Mar 2028

Est. completion

P2Relapsed and Refractory Multiple Myeloma

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

NCT05530421n=33

Apr 2029

Est. completion

P1Multiple Myeloma

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

NCT07200102n=20

May 2030

Est. completion

P2Myelofibrosis

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

NCT07447817n=26

Aug 2030

Est. completion

P2Ovarian Cancer

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05983276n=40

Sep 2035

Est. completion

Polycythemia Vera

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT07362225n=5,000

Awaiting Results (9)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870

May 2026

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

NCT04782687

May 2026

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931

Mar 2026

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348

Feb 2026

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389

Dec 2025

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

NCT04717700

Aug 2024

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04925193

Jul 2023

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT04898894

Feb 2018

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245

Recent Press Releases

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

Nov 4, 2026 · PRNewsWire

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

Nov 2, 2026 · PRNewsWire

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2026 · PRNewsWire

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 1, 2026 · PRNewsWire

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Aug 31, 2026 · PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Aug 27, 2026 · PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Aug 25, 2026 · GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Aug 20, 2026 · PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Aug 18, 2026 · GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

Aug 13, 2026 · PRNewsWire

SEC Filings (98)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	8-K	Material event	Document Index
Nov 3, 2026	8-K	Material event	Document Index
Nov 2, 2026	8-K	Material event	Document Index
Oct 28, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Oct 22, 2026	8-K	Material event	Document Index
Oct 14, 2026	8-K	Material event	Document Index
Oct 8, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Sep 25, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Sep 25, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Sep 18, 2026	8-K	Material event	Document Index
Sep 11, 2026	8-K	Material event	Document Index
Sep 4, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 31, 2026	8-K	Material event	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 13, 2026	10-Q	Quarterly report	Document Index
Aug 13, 2026	8-K	Material event	Document Index
Aug 12, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 11, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jul 31, 2026	8-K	Material event	Document Index
Jul 28, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 17, 2026	8-K	Material event	Document Index
Jun 5, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 28, 2026	8-K	Material event	Document Index
May 27, 2026	S-8	Employee stock plan	Document Index
May 27, 2026	S-8	Employee stock plan	Document Index
May 15, 2026	SC 13G	Passive 5%+ stake	Document Index
May 15, 2026	SC 13G	Passive 5%+ stake	Document Index
May 14, 2026	EFFECT		Document Index
May 14, 2026	EFFECT		Document Index
May 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 14, 2026	10-Q	Quarterly report	Document Index
May 14, 2026	8-K	Material event	Document Index
May 13, 2026	SC 13G	Passive 5%+ stake	Document Index
May 12, 2026	SC 13G	Passive 5%+ stake	Document Index
May 11, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 4, 2026	S-3	Shelf registration	Document Index
May 4, 2026	S-3	Shelf registration	Document Index
Apr 13, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Apr 13, 2026	ARS	Annual report to holders	Document Index